Perspectives in GLP-1 Research: New Targets, New Receptors

[1]  C. Diéguez,et al.  Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets , 2016, Trends in Endocrinology & Metabolism.

[2]  Gloria Torres,et al.  Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation. , 2016, Biochemical pharmacology.

[3]  W. White,et al.  Cardiovascular Effects of Incretin-Based Therapies. , 2016, Annual review of medicine.

[4]  J. Egan,et al.  Does GLP-1 suppress its own basal secretion? , 2016, Endocrine research.

[5]  S. Madsbad.  Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists , 2015, Diabetes, obesity & metabolism.

[6]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[7]  Wei Wang,et al.  GLP-1 contributes to increases in PGC-1α expression by downregulating miR-23a to reduce apoptosis. , 2015, Biochemical and biophysical research communications.

[8]  M. Yoshizumi,et al.  Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways , 2015, PloS one.

[9]  Deepak L. Bhatt,et al.  Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial , 2015, Diabetes Care.

[10]  B. Joo,et al.  Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes , 2015, Journal of menopausal medicine.

[11]  F. Lin,et al.  Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism , 2015, Journal of cardiovascular pharmacology.

[12]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[13]  I. Dicembrini,et al.  Drugs for type 2 diabetes: role in the regulation of bone metabolism. , 2015, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[14]  D. D’Alessio,et al.  Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. , 2015, Physiological reviews.

[15]  P. Reaven,et al.  Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans , 2015, Diabetes.

[16]  G. Forti,et al.  Effect of liraglutide on proliferation and differentiation of human adipose stem cells , 2015, Molecular and Cellular Endocrinology.

[17]  Wei Jiang,et al.  Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways , 2015, Cardiovascular Diabetology.

[18]  V. Kanamarlapudi,et al.  The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression , 2014, Scientific Reports.

[19]  Bo Hyun Kim,et al.  Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells , 2014, Endocrinology and metabolism.

[20]  D. Drucker,et al.  Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. , 2014, The Journal of clinical investigation.

[21]  R. Seeley,et al.  Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. , 2014, The Journal of clinical investigation.

[22]  R. Seeley,et al.  Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotectionab , 2014, Molecular metabolism.

[23]  Simon C. Cork,et al.  Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse Model , 2014, Diabetes.

[24]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[25]  R. Seeley,et al.  Hormones and diet, but not body weight, control hypothalamic microglial activity , 2014, Glia.

[26]  D. Chappard,et al.  Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. , 2013, The Journal of endocrinology.

[27]  P. Doevendans,et al.  Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. , 2013, International journal of cardiology.

[28]  D. Giugliano,et al.  Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes , 2013, Diabetes Care.

[29]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[30]  Lei Gong,et al.  Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. , 2013, International journal of molecular medicine.

[31]  Jun Ren,et al.  Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism , 2013, Diabetes.

[32]  T. Shibasaki,et al.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure , 2013, Nature Medicine.

[33]  J. Ayala,et al.  Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. , 2013, American journal of physiology. Cell physiology.

[34]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[35]  Yukio Fujiwara,et al.  Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. , 2012, Biochemical and biophysical research communications.

[36]  I. Dicembrini,et al.  Bone: Incretin Hormones Perceiver or Receiver? , 2012, Experimental diabetes research.

[37]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[38]  N. Marchionni,et al.  Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis , 2012, Experimental diabetes research.

[39]  M. J. Charron,et al.  Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. , 2012, Endocrinology.

[40]  D. Donnelly,et al.  The structure and function of the glucagon‐like peptide‐1 receptor and its ligands , 2012, British journal of pharmacology.

[41]  I. Dicembrini,et al.  Incretin-based therapies and cardiovascular risk , 2012, Current medical research and opinion.

[42]  C. Hölscher,et al.  Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis , 2012, BMC Neuroscience.

[43]  L. Tao,et al.  Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism , 2012, Diabetes.

[44]  C. Mcintosh,et al.  Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization , 2012, PloS one.

[45]  N. Al-Daghri,et al.  GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress , 2012, Regulatory Peptides.

[46]  W. Langhans,et al.  Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling* , 2011, The Journal of Biological Chemistry.

[47]  M. Monami,et al.  Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures , 2011, Diabetes Care.

[48]  H. Grill,et al.  Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. , 2011, Endocrinology.

[49]  I. Valverde,et al.  Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients , 2011, Regulatory Peptides.

[50]  N. Marchionni,et al.  Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities , 2011, Experimental diabetes research.

[51]  M. Taskinen,et al.  Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[52]  P. J. Larsen,et al.  Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides , 2010, Progress in Neurobiology.

[53]  S. Portal-Nuñez,et al.  Presence of a functional receptor for GLP‐1 in osteoblastic cells, independent of the cAMP‐linked GLP‐1 receptor , 2010, Journal of cellular physiology.

[54]  L. Miller,et al.  Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. , 2010, American journal of physiology. Endocrinology and metabolism.

[55]  E. Diamandis,et al.  Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. , 2010, Endocrinology.

[56]  P. Whitton,et al.  Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection , 2010, British journal of pharmacology.

[57]  E. Tomás,et al.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis , 2010, Trends in Endocrinology & Metabolism.

[58]  G. Willars,et al.  Role of the signal peptide in the synthesis and processing of the glucagon‐like peptide‐1 receptor , 2010, British Journal of Pharmacology.

[59]  Y. Nakaya,et al.  Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. , 2009, Biochemical and biophysical research communications.

[60]  J. Holst,et al.  Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. , 2009, Bone.

[61]  P. Tso,et al.  Stimulation of incretin secretion by dietary lipid: is it dose dependent? , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[62]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[63]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[64]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[65]  T. Engstrøm,et al.  Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart , 2008, Regulatory Peptides.

[66]  J. Holst,et al.  The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. , 2007, The Journal of clinical endocrinology and metabolism.

[67]  G. Ning,et al.  GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes , 2007, Endocrine.

[68]  S. Woods,et al.  Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. , 2007, Endocrinology.

[69]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[70]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[71]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[72]  W. Malaisse,et al.  Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. , 2005, Journal of molecular endocrinology.

[73]  S. Theander,et al.  β-Cell Secretory Products Activate α-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release , 2005 .

[74]  D. D’Alessio,et al.  Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[75]  I. Valverde,et al.  Cell signalling of the GLP-1 action in rat liver , 2003, Molecular and Cellular Endocrinology.

[76]  Y. Ikezawa,et al.  Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically , 2003, Regulatory Peptides.

[77]  I. Valverde,et al.  Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. , 2002, The Journal of endocrinology.

[78]  P. J. Larsen,et al.  Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. , 1997, Endocrinology.

[79]  Yihong Wang,et al.  Novel signal transduction and peptide specificity of glucagon‐like peptide receptor in 3T3‐L1 adipocytes , 1997, Journal of cellular physiology.

[80]  E. Nishimura,et al.  Regulation of glucagon receptor expression. , 1996, Acta physiologica Scandinavica.

[81]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[82]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[83]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[84]  I. Valverde,et al.  Glucagon‐like peptide 1: A potent glycogenic hormone , 1994, FEBS letters.

[85]  J. Holst,et al.  Complete sequences of glucagon-like peptide-1 from human and pig small intestine. , 1989, The Journal of biological chemistry.

[86]  A. Schwartz,et al.  Effects of diabetes drugs on the skeleton. , 2016, Bone.